Augmentation of cellular immunity by kigamicin D.
Kigamicin D did not show any immunosuppressive activity in mixed lymphocyte culture reaction and mitogen induced lymphocyte blastogenesis in vitro and graft versus host reaction in vivo. Natural killer cell activity in spleen cells was not affected by oral administration of kigamicin D. Instead, delayed-type hypersensitivity response to sheep red blood cells was stimulated at a broad dosage level. It is concluded that kigamicin D increases cellular immunity to specific antigen.
Masuda
Toru
T
Numazu Bio-Medical Research Institute, Microbial Chemistry Research Center, 18-24 Miyamoto, Numazu-shi, Shizuoka 410-0301, Japan. masudat@bikaken.or.jp
Ohba
Shunichi
S
Kawada
Manabu
M
Iijima
Masatomi
M
Inoue
Hiroyuki
H
Osono
Michiyo
M
Ikeda
Daishiro
D
Kunimoto
Setsuko
S
D000818:Animals; D002478:Cells, Cultured; D004317:Doxorubicin / Q000031:analogs & derivatives* / Q000494:pharmacology; D006087:Graft vs Host Reaction / Q000187:drug effects; D006968:Hypersensitivity, Delayed; D007111:Immunity, Cellular / Q000187:drug effects*; D007694:Killer Cells, Natural / Q000187:drug effects; D008213:Lymphocyte Activation / Q000187:drug effects; D007959:Lymphocyte Culture Test, Mixed; D051379:Mice; D008809:Mice, Inbred C3H; D023421:Models, Animal; D010080:Oxazoles / Q000494:pharmacology*; D013154:Spleen / Q000276:immunology
D010080:Oxazoles; C484110:kigamicin D; D004317:Doxorubicin